Steroid-free disease management
AssigneeAsana Biosciences, LLC
InventorsRoger Astbury Smith, Nicholas James Laping, Sandeep Gupta
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of the compound 1-(2-(4-fluorophenyl)thiazol-5-yl)-1-(pyridin-4-yl)ethanol (“ASNOO1”) in treatments without concomitant use of a steroid and/or in the form of a racemic mixture, e.g. in prostate cancer treatment. It also relates to its use in methods that are food indifferent.
Claims29
A method of treating a human patient having prostate cancer comprising:
- administering orally to a human patient in need thereof a therapeutically effective amount of racemic ASN001 ranging from about 10 mg to about 2 grams in no more than 2 doses per day for at least 14 consecutive days.
A method of treating a cancer susceptible to testosterone deprivation in a human patient suffering from same comprising:
- administering orally to a human patient in need thereof a chemotherapeutic regimen consisting essentially of a therapeutically effective amount of ASN001 ranging from about 10 mg to about 2 grams daily in 1 to 4 doses per day for at least 14 consecutive days.
A daily chemotherapeutic regimen of ASN001 suitable for administration to a human patient comprising:
- oral dosage forms containing from about 10 mg to about 2 grams of racemic ASN001 divided into from 1 to 4 daily doses.
A solid oral dosage form comprising:
- about 25 to about 400 mg of racemic ASN001 and at least one excipient.
A solid oral dosage form comprising:
- about 25 to about 400 mg of a mixture of enantiomers ASN001 and at least one excipient.
A solid oral dosage form comprising:
- about 25 to about 400 mg of a substantially pure enantiomer of ASN001 and at least one excipient.
Dependencies are inferred from the claim text.